Scott Rocklage’s track record since joining 5AM Ventures as a venture partner in 2003 is marked by milestone after milestone. He has overseen the company grown its drug research and manufacturing efforts as well as expanding its operations through investments in various firms including startups. These milestones have been accomplished through his dedication to scientific research, vast industry experience and a solid academic background.
He has overseen the growth of the company’s investment portfolio by investing millions of dollars in seed money and Series A investment in various pharmaceutical companies and startups such as Achaogen, Novira, Pulmatrix and Rennovia.
To safeguard 5AM Ventures interests and investments, he has been appointed as a member of the board of directors in these firms. Learn more about Scott Rocklage: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift
Academic and Professional Profile
Scott Rocklage has accumulated over three decades both as a professional and an entrepreneur. His long journey in the industry began with a Bachelor of Science degree from University of California, Berkeley where he specialized in Chemistry. He later joined the Massachusetts Institute of Technology where he graduated with a Doctor of Philosophy degree in Chemistry.
Despite serving as a managing partner at 5AM Ventures, Scott Rocklage also serves on the board of several companies including Relypsa, Novira Therapeutics, Whitehead Institute for Biomedical Research and Epirus Biopharmaceuticals. This is in addition to his membership to the various companies he has invested in through 5AM Ventures.
Scott Rocklage served as the president of Cubist Pharmaceuticals Inc. from 1994 to 2001. This overlapped with his chief executive officer’s tenure, which ended in 2001. His duties at Cubist also overlapped with his tenure as the president and chief executive officer of Nycomed Salutar Inc. between 1990 and 1994.
Between 1992 and 1994, he served as the chief executive officer, chairman and president of Nycomed International Inc. He previously headed Catalytica’s research and development department while serving as the executive chairman of Ilypsa and Entremed among others.
Successes at 5AM Ventures: Beyond Venture Capital Investments
Scott Rocklage is a reputable research scientist whose scientific endeavors have seen him publish over a hundred scientific publications. He is also an inventor with close to thirty patents registered to his name or other co-workers.
These skills and background have especially played a critical in the numerous drugs that 5AM Ventures has already released to the market after approval by the FDA.